Cullinan Therapeutics, Inc.
US ˙ NasdaqGS ˙ US2300311063

SecurityCGEM / Cullinan Therapeutics, Inc.
InstitutionBarclays Plc
Latest Disclosed Ownership269,655 shares
Latest Disclosed Value $ 2,790,930
Barclays Plc reports 7.39% increase in ownership of CGEM / Cullinan Therapeutics, Inc.

On February 13, 2026 - Barclays Plc filed a 13F-HR form disclosing ownership of 269,655 shares of Cullinan Therapeutics, Inc. (US:CGEM) valued at $2,790,929 USD as of December 31, 2025. The entity filed a previous 13F-HR/A on March 31, 2026 disclosing 251,110 shares of Cullinan Therapeutics, Inc.. This represents a change in shares of 7.39% during the quarter. The current value of the position is $3,891,122 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-02-13 2025-12-31 13F CULLINAN THERAPEUTICS COM 230031106 269,655 18,545 7.39 2,791 87.37 0.0007
2026-03-31 2025-09-30 13F/A-3 CULLINAN THERAPEUTICS COM 230031106 251,110 -17,357 -6.47 1,489 -26.32 0.0003
2026-03-19 2025-09-30 13F/A-2 CULLINAN THERAPEUTICS COM 230031106 248,614 -19,853 4,162 0.0011
2025-11-12 2025-09-30 13F CULLINAN THERAPEUTICS COM 230031106 251,110 -17,357 1,489 0.0003
2026-02-27 2025-06-30 13F/A-2 CULLINAN THERAPEUTICS COM 230031106 268,467 27,124 11.24 2,022 10.68 0.0005
2025-08-14 2025-06-30 13F/A-1 CULLINAN THERAPEUTICS COM 230031106 268,467 27,124 2 0.0005
2025-08-13 2025-06-30 13F CULLINAN THERAPEUTICS COM 230031106 268,467 27,124 2 0.0002
2026-03-17 2025-03-31 13F/A-1 CULLINAN THERAPEUTICS COM 230031106 241,343 -3,888 -1.59 1,827 -38.85 0.0005
2025-05-15 2025-03-31 13F CULLINAN THERAPEUTICS COM 230031106 241,343 -3,888 2 0.0005
2026-03-19 2024-12-31 13F/A-1 CULLINAN THERAPEUTICS COM 230031106 245,231 -3,383 -1.36 2,987 -28.24 0.0008
2025-02-13 2024-12-31 13F CULLINAN THERAPEUTICS COM 230031106 245,231 -3,383 3 0.0008
2026-03-31 2024-09-30 13F/A-2 CULLINAN THERAPEUTICS COM 230031106 248,614 51,300 26.00 4,162 20.92 0.0011
2024-11-19 2024-09-30 13F/A-1 CULLINAN THERAPEUTICS COM 230031106 248,614 51,300 4 0.0011
2024-11-15 2024-09-30 13F CULLINAN THERAPEUTICS COM 230031106 248,614 51,300 4 0.0011
2026-03-23 2024-06-30 13F/A-1 CULLINAN THERAPEUTICS COM 230031106 197,314 157,122 390.93 3,441 403.07 0.0011
2024-08-14 2024-06-30 13F CULLINAN THERAPEUTICS COM 230031106 197,314 157,122 3 0.0011
2026-03-24 2024-03-31 13F/A-1 CULLINAN ONCOLOGY COM 230031106 40,192 -45,032 -52.84 685 -21.20 0.0002
2024-05-15 2024-03-31 13F CULLINAN ONCOLOGY COM 230031106 40,192 -45,032 1 0.0002
2026-03-25 2023-12-31 13F/A-1 CULLINAN ONCOLOGY COM 230031106 85,224 31,831 59.62 868 79.71 0.0003
2024-02-15 2023-12-31 13F CULLINAN ONCOLOGY COM 230031106 85,224 31,831 1 0.0003
2026-03-26 2023-09-30 13F/A-1 CULLINAN ONCOLOGY COM 230031106 53,393 31,650 145.56 483 107.30 0.0003
2023-11-07 2023-09-30 13F CULLINAN ONCOLOGY COM 230031106 53,393 31,650 0 0.0003
2026-03-30 2023-06-30 13F/A-2 CULLINAN ONCOLOGY COM 230031106 21,743 -6,570 -23.20 234 -19.38 0.0001
2023-09-20 2023-06-30 13F/A-1 CULLINAN ONCOLOGY COM 230031106 21,743 -6,570 0 0.0001
2023-08-03 2023-06-30 13F CULLINAN ONCOLOGY COM 230031106 21,743 -6,570 0 0.0001
2026-03-30 2023-03-31 13F/A-1 CULLINAN ONCOLOGY COM 230031106 28,313 6,817 31.71 290 27.88 0.0001
2023-05-04 2023-03-31 13F CULLINAN ONCOLOGY COM 230031106 28,313 6,817 0 0.0001
2026-03-30 2022-12-31 13F/A-1 CULLINAN ONCOLOGY COM 230031106 21,496 12,502 139.00 227 94.83 0.0001
2023-02-13 2022-12-31 13F CULLINAN ONCOLOGY COM 230031106 21,496 12,502 0 0.0001
2022-11-03 2022-09-30 13F CULLINAN ONCOLOGY COM 230031106 8,994 1,731 23.83 116 24.73 0.0001
2022-08-12 2022-06-30 13F CULLINAN ONCOLOGY COM 230031106 7,263 -65 -0.89 93 20.78 0.0001
2022-05-16 2022-03-31 13F CULLINAN ONCOLOGY COM 230031106 7,328 7,328 77 0.0001
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.